EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Revelation Biosciences's enterprise value is $-1.52 Mil.
Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Revelation Biosciences's EV-to-Revenue for today is .
The historical rank and industry rank for Revelation Biosciences's EV-to-Revenue or its related term are showing as below:
REVB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.38 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Revelation Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Revelation Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revelation Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Revelation Biosciences's EV-to-Revenue falls into.
Revelation Biosciences's current Enterprise Value is $-1.52 Mil.
Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences's share price for today is $1.93.
Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revelation Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Revelation Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
REVB has been successfully added to your 